Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology

Open Access 10-10-2023 | Mood Disorders | Original Paper

Incidence of depression in patients with cardiovascular disease and type 2 diabetes: a nationwide cohort study

Authors: Bochra Zareini, Katrine Kold Sørensen, Paul Blanche, Alexander C. Falkentoft, Emil Fosbøl, Lars Køber, Christian Torp-Pedersen

Published in: Clinical Research in Cardiology

Login to get access

Abstract

Background

Estimating how type 2 diabetes (T2D) affects the rate of depression in cardiovascular disease (CVD) can help identify high-risk patients. The aim is to investigate how T2D affects the rate of depression according to specific subtypes of CVD.

Methods

Incident CVD patients, free of psychiatric disease, with and without T2D, were included from nationwide registries between 2010 and 2020. We followed patients from CVD diagnosis until the first occurrence of depression, emigration, death, 5 years, or end of study (December 31, 2021). We used time-dependent Poisson regression to estimate the incidence rates and rate ratios (IRR) of depression following subtypes of CVD with and without T2D. The model included age, sex, comorbidities, calendar year, T2D duration, educational level, and living situation as covariates.

Results

A total of 165,096 patients were included; 45,845 had a myocardial infarction (MI), 63,691 had a stroke, 19,959 had peripheral artery disease (PAD), 35,568 had heart failure (HF), and 979 were diagnosed with 2 or more CVD subtypes (= > 2 CVD’s). Baseline T2D in each CVD subtype ranged from 11 to 17%. The crude incidence rate of depression per 1000 person-years (95% confidence intervals) was: MI + T2D: 131.1 (109.6;155.6), MI: 82.1 (65.3;101.9), stroke + T2D: 287.4 (255.1;322.6), stroke: 222.4(194.1;253.6), PAD + T2D: 173.6 (148.7;201.4), PAD:137.5 (115.5;162.5), HF + T2D: 244.3 (214.6;276.9), HF: 199.2 (172.5;228.9), =  > 2 CVD’s + T2D: 427.7 (388.1;470.2), =  > 2 CVD’s: 372.1 (335.2;411.9). The adjusted IRR of depression in MI, stroke, PAD, HF, and =  > 2 CVD’s with T2D compared to those free of T2D was: 1.29 (1.23;1.35), 1.09 (1.06;1.12), 1.18 (1.13;1.24), 1.05 (1.02;1.09), and 1.04 (0.85;1.27) (p-value for interaction < 0.001).

Conclusion

The presence of T2D increased the rate of depression differently among CVD subtypes, most notable in patients with MI and PAD.
Appendix
Available only for authorised users
Literature
1.
Bădescu S, Tătaru C, Kobylinska L, Georgescu E, Zahiu D, Zăgrean A, Zăgrean L (2016) The association between diabetes mellitus and depression. J Med Life 9:120–125PubMedPubMedCentral
2.
3.
Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan KRR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M, Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701–709CrossRefPubMed
4.
Writing Committee for the ENRICHD Investigators (2003) Effects of treating depression and low perceived social support on clinical events after myocardial infarction the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA 289:3106–3116CrossRef
5.
Lespérance F, Frasure-Smith N, Koszycki D, Laliberté M-A, van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson BL, Dorian P, Guertin M-C, Guertin M-C, CREATE Investigators for the (2007) Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA 297:367CrossRefPubMed
6.
Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM, O’Hayer CVF, Mabe S, Johnson J, Doraiswamy PM, Jiang W, Schocken DD, Hinderliter AL (2012) Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease. J Am Coll Cardiol 60:1053–1063CrossRefPubMedPubMedCentral
7.
O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R (2010) Safety and efficacy of sertraline for depression in patients with heart failure. J Am Coll Cardiol 56:692–699CrossRefPubMedPubMedCentral
8.
Hare DL, Toukhsati SR, Johansson P, Jaarsma T (2014) Depression and cardiovascular disease: a clinical review. Eur Heart J 35:1365–1372CrossRefPubMed
9.
Wynn A (1967) unwarranted emotional distress in men with ischaemic heart disease (IHD). Med J Aust 2:847–851CrossRefPubMed
10.
Nouwen A, Adriaanse MC, van Dam K, Iversen MM, Viechtbauer W, Peyrot M, Caramlau I, Kokoszka A, Kanc K, de Groot M, Nefs G, Pouwer F (2019) Longitudinal associations between depression and diabetes complications: a systematic review and meta-analysis. Diabet Med 36:1562–1572CrossRefPubMed
11.
Semenkovich K, Brown ME, Svrakic DM, Lustman PJ (2015) Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. Drugs 75:577–587CrossRefPubMed
12.
Brieler JA, Lustman PJ, Scherrer JF, Salas J, Schneider FD (2016) Antidepressant medication use and glycaemic control in co-morbid type 2 diabetes and depression. FAMPRJ 33:30–36CrossRef
13.
SAXENDA (liraglutide [rDNA origin] injection). 40
14.
Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen A-MS, Gislason GH, Torp-Pedersen C (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342:124CrossRef
15.
Gillespie BW, Chen Q, Reichert H, Franzblau A, Hedgeman E, Lepkowski J, Adriaens P, Demond A, Luksemburg W, Garabrant DH (2010) Estimating population distributions when some data are below a limit of detection by using a reverse Kaplan–Meier estimator. Epidemiology 21:S64–S70CrossRefPubMed
16.
Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, Schrag D, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, Wei L-J (2014) Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol 32:2380–2385CrossRefPubMedPubMedCentral
17.
R Core Team. R: A Language and Environment for Statistical Computing
18.
Jacob L, Kostev K (2016) Prevalence of depression in type 2 diabetes patients in German primary care practices. J Diabetes Complications 30:432–437CrossRefPubMed
19.
Pan H-H, Li C-Y, Chen P-C, Lee M-D, Liang C-Y, Hou W-H, Wang K-Y (2012) Contributions of diabetic macro-vascular complications and hip fracture to depression onset in elderly patients with diabetes: an 8-year population-based follow-up study. J Psychosom Res 73:180–184CrossRefPubMed
20.
van Sloten TT, Henry RMA, Dekker JM, Nijpels G, Unger T, Schram MT, Stehouwer CDA (2014) Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the hoorn study. Hypertension 64:1299–1305CrossRefPubMed
21.
Forouhi NG, Luan J, Hennings S, Wareham NJ (2007) Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990–2000. Diabet Med 24:200–207CrossRefPubMed
22.
Schram MT, Henry RMA, van Dijk RAJM, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Westerhof N, Stehouwer CDA (2004) Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the hoorn study. Hypertension 43:176–181CrossRefPubMed
23.
Mostaza JM, Lahoz C, Salinero-Fort MA, de Burgos-Lunar C, Laguna F, Estirado E, García-Iglesias F, González-Alegre T, Cornejo-Del-Río V, Sabín C, López S (2015) Carotid atherosclerosis severity in relation to glycemic status: a cross-sectional population study. Atherosclerosis 242:377–382CrossRefPubMed
24.
Lee JF, Barrett-O’Keefe Z, Garten RS, Nelson AD, Ryan JJ, Nativi JN, Richardson RS, Wray DW (2016) Evidence of microvascular dysfunction in heart failure with preserved ejection fraction. Heart 102:278–284CrossRefPubMed
25.
Gamrat A, Surdacki MA, Chyrchel B, Surdacki A (2020) Endothelial dysfunction: a contributor to adverse cardiovascular remodeling and heart failure development in type 2 diabetes beyond accelerated atherogenesis. J Clin Med 9:2090CrossRefPubMedPubMedCentral
26.
Buysschaert M, Medina JL, Bergman M, Shah A, Lonier J (2015) Prediabetes and associated disorders. Endocrine 48:371–393CrossRefPubMed
27.
Wong M-S, Gu K, Heng D, Chew S-K, Chew L-S, Tai ES (2003) The Singapore impaired glucose tolerance follow-up study: does the ticking clock go backward as well as forward? Diabetes Care 26:3024–3030CrossRefPubMed
28.
Ford ES, Zhao G, Li C (2010) Pre-diabetes and the risk for cardiovascular disease. J Am Coll Cardiol 55:1310–1317CrossRefPubMed
29.
van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer CDA (2020) Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol 8:325–336CrossRefPubMed
30.
Brouwers C, Christensen SB, Damen NL, Denollet J, Torp-Pedersen C, Gislason GH, Pedersen SS (2016) Antidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression. Int J Cardiol 203:867–873CrossRefPubMed
31.
Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ (2006) Depression in heart failure. J Am Coll Cardiol 48:1527–1537CrossRefPubMed
32.
Fan H, Yu W, Zhang Q, Cao H, Li J, Wang J, Shao Y, Hu X (2014) Depression after heart failure and risk of cardiovascular and all-cause mortality: a meta-analysis. Prev Med 63:36–42CrossRefPubMed
33.
Sokoreli I, de Vries JJG, Pauws SC, Steyerberg EW (2016) Depression and anxiety as predictors of mortality among heart failure patients: systematic review and meta-analysis. Heart Fail Rev 21:49–63CrossRefPubMed
34.
Adelborg K, Schmidt M, Sundbøll J, Pedersen L, Videbech P, Bøtker HE, Egstrup K, Sørensen HT (2016) Mortality risk among heart failure patients with depression: a nationwide population-based cohort study. J Am Heart Assoc 5:2CrossRef
35.
Schmidt M, Pedersen L, Sørensen HT (2014) The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 29:541–549CrossRefPubMed
36.
Carstensen B, Kristensen JK, Marcussen MM, Borch-Johnsen K (2011) The national diabetes register. Scand J Public Health 39:58–61CrossRefPubMed
37.
Adelborg K, Sundbøll J, Munch T, Frøslev T, Sørensen HT, Bøtker HE, Schmidt M (2016) Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: a population-based validation study. BMJ Open 6:e012817CrossRefPubMedPubMedCentral
38.
Sundbøll J, Adelborg K, Munch T, Frøslev T, Sørensen HT, Bøtker HE, Schmidt M (2016) Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open 6:e012832CrossRefPubMedPubMedCentral
Metadata
Title
Incidence of depression in patients with cardiovascular disease and type 2 diabetes: a nationwide cohort study
Authors
Bochra Zareini
Katrine Kold Sørensen
Paul Blanche
Alexander C. Falkentoft
Emil Fosbøl
Lars Køber
Christian Torp-Pedersen
Publication date
10-10-2023
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-023-02311-3